Drugs / Etanercept
Etanercept
also known as
Enbrel · ETN · TNFR:Fc · ENIA11 · GP2015 · MB04 · 50mg entanercept(Yisaipu) · Benepali · +12 more
Protein / enzyme biologic targets TNF via inhibition
Regulatory milestones approvals, filings & regulatory actions · 19 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (17) | US (FDA) | ENBREL | — | 1999-05-27 – 2023-10-18 | fda.gov ↗ |
| Approved | EU (EMA) | Enbrel | — | 2000-02-02 | europa.eu ↗ |
| Approved | US (FDA) | ENBREL | — | 1998-11-02 | fda.gov ↗ |
Trials 246 · started per year
today
US approved 1998
EU approved 2000
2
1
7
8
6
11
10
18
18
14
14
17
14
8
10
8
8
6
8
15
6
3
4
3
7
3
3
2
4
4
19971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 04 trials | ||||||
| Phase 0 | NCT05950724 | Sep 2023 → Dec 2026 expected | — | Northwestern University | Enrolling by invitation | No outcome recorded |
| Phase 0 | NCT05281614 | Sep 2022 → Jan 2024 | type 1 diabetes mellitus | Benaroya Research Institute | Completed | No outcome recorded |
| Phase 0 | NCT00965666 | Oct 2005 → Oct 2010 | Fanconi anemia | Children's Hospital Medical Center, Cincinnati | Completed | No outcome recorded |
| Phase 0 | NCT00802815 | Apr 2005 → May 2014 | inclusion body myositis | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 123 trials | ||||||
| Phase 1 | NCT04585711 | Jul 2026 → Feb 2027 | juvenile idiopathic arthritis, obesity disorder, rheumatoid arthritis | Duke University | Withdrawn | No outcome recorded |
| Phase 1 | NCT06585384 | Apr 2025 → Jun 2028 expected | Alzheimer disease | Fondation Ophtalmologique Adolphe de Rothschild | Recruiting | No outcome recorded |
| Phase 1 | NCT06392074 | Mar 2024 → May 2025 | — | mAbxience Research S.L. | Completed | No outcome recorded |
| Phase 1 | NCT04973566 | Aug 2021 → May 2022 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT04559412 | Mar 2021 → Jan 2024 | rheumatoid arthritis | Sorrento Therapeutics, Inc. | Unknown | No outcome recorded |
| Phase 1 | NCT01865630 | Jan 2021 → Jan 2022 | acquired aneurysmal subarachnoid hemorrhage | Unity Health Toronto | Withdrawn | No outcome recorded |
| Phase 1 | NCT03294954 | Jan 2018 → Dec 2027 expected | neuroblastoma | Baylor College of Medicine | Recruiting | No outcome recorded |
| Phase 1 | NCT04255498 | Oct 2017 → Aug 2019 | occupational disorder, persian gulf syndrome | South Florida Veterans Affairs Foundation for Research and Education | Unknown | No outcome recorded |
| Phase 1 | NCT03193203 | Mar → Aug 2017 | — | Samsung Bioepis Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03273088 | Dec 2016 → Mar 2017 | — | AryoGen Pharmed Co. | Completed | No outcome recorded |
| Phase 1 | NCT02999776 | Nov 2016 → Dec 2017 | psoriasis | Pantec Biosolutions AG | Unknown | No outcome recorded |
| Phase 1 | NCT01894412 | Jul 2013 → Dec 2015 | — | Hanwha Chemical | Completed | No outcome recorded |
| Phase 1 | NCT01865552 | May → Aug 2013 | — | Samsung Bioepis Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01725620 | Nov 2012 → Apr 2013 | — | LG Life Sciences | Completed | No outcome recorded |
| Phase 1 | NCT01294397 | Mar 2011 → Jan 2016 | postmenopausal osteoporosis, rheumatoid arthritis | Amgen | Terminated | No outcome recorded |
| Phase 1 | NCT01145950 | Jun → Nov 2010 | — | LG Life Sciences | Completed | No outcome recorded |
| Phase 1 | NCT00705042 | Jul → Sep 2008 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00502879 | Jul → Aug 2007 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00361634 | Sep 2006 → Aug 2009 | rheumatoid arthritis | Amgen | Completed | No outcome recorded |
| Phase 1 | NCT00203320 | Apr 2005 → Jan 2006 | Alzheimer disease | Tobinick, Edward Lewis, M.D. | Completed | No outcome recorded |
| Phase 1 | NCT00203359 | Sep 2004 → Apr 2006 | Alzheimer disease | Tobinick, Edward Lewis, M.D. | Completed | No outcome recorded |
| Phase 1 | NCT00201812 | Nov 2000 → Jan 2004 | neoplasm | Ohio State University Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00091741 | ? → Oct 2004 | HIV infectious disease | Georgetown University | Completed | No outcome recorded |
| Phase 1/210 trials | ||||||
| Phase 1/2 | NCT03182426 | Aug 2017 → Jul 2024 | type 1 diabetes mellitus | University of Alberta | Completed | No outcome recorded |
| Phase 1/2 | NCT02112097 | Jan → Jun 2016 | psoriasis | ASIS Corporation | Unknown | No outcome recorded |
| Phase 1/2 | NCT00585650 | May 2007 → May 2008 | psoriasis | University of California, Irvine | Completed | No outcome recorded |
| Phase 1/2 | NCT00364572 | May 2006 → Dec 2007 | sciatica | Johns Hopkins University | Completed | No outcome recorded |
| Phase 1/2 | NCT00118287 | Apr 2005 → Oct 2008 | myelodysplastic syndrome | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00093366 | Jun 2004 → Jul 2006 | leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00201682 | Oct 2002 → Aug 2006 | chronic lymphocytic leukemia/small lymphocytic lymphoma | John Byrd | Completed | No outcome recorded |
| Phase 1/2 | NCT00730392 | Oct 2002 → Oct 2007 | type 1 diabetes mellitus | State University of New York at Buffalo | Completed | No outcome recorded |
| Phase 1/2 | NCT00029328 | Sep 2001 → Sep 2003 | adult acute respiratory distress syndrome, pneumonia, transplant-related bronchiolitis obliterans | FDA Office of Orphan Products Development | Completed | No outcome recorded |
| Phase 1/2 | NCT00201838 | Jul 2001 → Oct 2006 | adenocarcinoma, pancreatic neoplasm | Ohio State University Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 244 trials | ||||||
| Phase 2 | NCT07138898 | Dec 2025 → Jan 2028 expected | rheumatic disorder | NYU Langone Health | Recruiting | No outcome recorded |
| Phase 2 | NCT04066348 | Jul 2022 → Sep 2026 expected | tinnitus | Wayne State University | Recruiting | No outcome recorded |
| Phase 2 | NCT03193957 | May → Aug 2017 | rheumatoid arthritis | Samsung Bioepis Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT02656082 | Feb 2016 → Dec 2017 | discoid lupus erythematosus | University of Leeds | Completed | No outcome recorded |
| Phase 2 | NCT02464033 | May 2015 → Feb 2019 | type 1 diabetes mellitus | Johnny Ludvigsson | Completed | No outcome recorded |
| Phase 2 | NCT01730495 | Oct 2012 → Aug 2014 | myalgic encephalomeyelitis/chronic fatigue syndrome | Haukeland University Hospital | Terminated | No outcome recorded |
| Phase 2 | NCT01731457 | Apr 2011 → Feb 2014 | — | Medical University of Warsaw | Completed | No outcome recorded |
| Phase 2 | NCT01068353 | Jan 2011 → Dec 2013 | Alzheimer disease | University of Southampton | Completed | No outcome recorded |
| Phase 2 | NCT01989689 | Aug 2010 → Sep 2013 | psoriasis | Emory University | Completed | No outcome recorded |
| Phase 2 | NCT02456363 | Nov 2009 → Oct 2019 | ankylosing spondylitis | Chung Shan Medical University | Unknown | No outcome recorded |
| Phase 2 | NCT00639717 | Mar 2009 → Jan 2012 | graft versus host disease | University of Michigan Rogel Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00841789 | Mar 2009 → Jan 2018 | Kawasaki disease | Michael Portman | Completed | No outcome recorded |
| Phase 2 | NCT00797784 | Oct 2008 → Apr 2011 | discoid lupus erythematosus | Florida Academic Dermatology Centers | Unknown | No outcome recorded |
| Phase 2 | NCT00447265 | Feb 2008 → Mar 2009 | lupus nephritis | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
| Phase 2 | NCT00285779 | Aug 2006 → Nov 2009 | lichen planus | Stanford University | Terminated | No outcome recorded |
| Phase 2 | NCT00309907 | Apr 2006 → Sep 2011 | Burkitt lymphoma, Hodgkins lymphoma, blast phase chronic myelogenous leukemia, BCR-ABL1 positive, childhood acute lymphoblastic leukemia +7 | Children's Oncology Group | Completed | No outcome recorded |
| Phase 2 | NCT00844142 | Nov 2005 → Jul 2013 | ankylosing spondylitis | Charite University, Berlin, Germany | Unknown | No outcome recorded |
| Phase 2 | NCT00224874 | Sep 2005 → Jan 2009 | graft versus host disease | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 2 | NCT00329823 | Sep 2005 → May 2006 | hidradenitis suppurativa | University of Athens | Completed | No outcome recorded |
| Phase 2 | NCT00141791 | May 2005 → Jul 2006 | asthma | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00678782 | Apr 2005 → Dec 2007 | synovitis | University of Padova | Completed | No outcome recorded |
| Phase 2 | NCT00107991 | Apr 2005 → Aug 2008 | hidradenitis suppurativa | University of Pennsylvania | Completed | No outcome recorded |
| Phase 2 | NCT00509600 | Sep 2004 → Apr 2009 | leukemia | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 2 | NCT00141739 | Aug 2004 → Aug 2011 | graft versus host disease | University of Michigan Rogel Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00135720 | Jun 2004 → Nov 2007 | pemphigus vulgaris | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00217386 | Mar 2004 → Dec 2007 | leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00134368 | Nov 2003 → Dec 2007 | vitiligo | University of Medicine and Dentistry of New Jersey | Completed | No outcome recorded |
| Phase 2 | NCT00141713 | Oct 2003 → Nov 2006 | acute graft versus host disease | University of Michigan Rogel Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00141726 | Oct 2003 → Jul 2008 | acute lung injury, adult acute respiratory distress syndrome, transplant-related bronchiolitis obliterans | University of Michigan Rogel Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00034060 | Apr 2002 → Dec 2005 | rheumatoid arthritis | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Completed | No outcome recorded |
| Phase 2 | NCT00031551 | Mar 2002 → Aug 2010 | stomatitis | National Institute of Nursing Research (NINR) | Terminated | No outcome recorded |
| Phase 2 | NCT01289743 | Feb 2002 → Sep 2003 | ankylosing spondylitis | Charite University, Berlin, Germany | Unknown | No outcome recorded |
| Phase 2 | NCT01289730 | Feb 2002 → Sep 2003 | spondyloarthropathy | Charite University, Berlin, Germany | Unknown | No outcome recorded |
| Phase 2 | NCT00048373 | Oct 2001 → Apr 2004 | Langerhans cell histiocytosis | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 2 | NCT00224393 | Feb 2001 → Aug 2005 | primary systemic amyloidosis | The Cleveland Clinic | Completed | No outcome recorded |
| Phase 2 | NCT00006070 | Jul 2000 → May 2004 | — | National Institute of Dental and Craniofacial Research (NIDCR) | Completed | No outcome recorded |
| Phase 2 | NCT00001954 | Dec 1999 → Nov 2003 | Sjogren syndrome | National Institute of Dental and Craniofacial Research (NIDCR) | Completed | No outcome recorded |
| Phase 2 | NCT00005853 | Dec 1999 → Aug 2005 | leukemia, myelodysplastic syndrome | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00001955 | Dec 1999 → Feb 2004 | temporomandibular joint disorder | National Institute of Dental and Craniofacial Research (NIDCR) | Completed | No outcome recorded |
| Phase 2 | NCT00000433 | Oct 1999 → Mar 2002 | ankylosing spondylitis | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Completed | No outcome recorded |
| Phase 2 | NCT00001893 | Aug 1999 → Dec 2002 | asthma | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 2 | NCT00001901 | Feb 1999 → Mar 2005 | granulomatosis with polyangiitis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT00001862 | Feb 1999 → Mar 2003 | juvenile idiopathic arthritis, uveitis | National Eye Institute (NEI) | Completed | No outcome recorded |
| Phase 2 | NCT00063869 | ? → Mar 2005 | idiopathic pulmonary fibrosis | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 2/39 trials | ||||||
| Phase 2/3 | NCT06011889 | Sep 2024 → Oct 2028 expected | SAPHO syndrome | National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland | Recruiting | No outcome recorded |
| Phase 2/3 | NCT03997786 | Jan 2020 → Apr 2025 overdue | psoriasis | Sun Pharmaceutical Industries, Inc. | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT00789997 | Nov 2008 → Aug 2011 | chronic obstructive pulmonary disease | Ottawa Hospital Research Institute | Completed | No outcome recorded |
| Phase 2/3 | NCT00733096 | Aug 2008 → Mar 2011 | radiculopathy | Johns Hopkins University | Completed | No outcome recorded |
| Phase 2/3 | NCT00111956 | Apr 2004 → May 2005 | metabolic syndrome X | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| Phase 2/3 | NCT00035958 | Aug 2002 | juvenile dermatomyositis | Children's Hospital Medical Center, Cincinnati | Terminated | No outcome recorded |
| Phase 2/3 | NCT00127387 | May 2001 → Sep 2005 | bone cancer, lung cancer, metastatic neoplasm, prostate cancer | The University of Texas Health Science Center at San Antonio | Terminated | No outcome recorded |
| Phase 2/3 | NCT00005007 | Jun 2000 → Mar 2003 | granulomatosis with polyangiitis | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Completed | No outcome recorded |
| Phase 2/3 | NCT03780959 | May 1997 → Jul 1998 | juvenile idiopathic arthritis | Amgen | Completed | No outcome recorded |
| Phase 362 trials | ||||||
| Phase 3 | NCT07386587 | Jan → Jul 2026 overdue | juvenile idiopathic arthritis | University of Child Health Sciences and Children's Hospital, Lahore | Enrolling by invitation | No outcome recorded |
| Phase 3 | NCT06654882 | Jan → Dec 2026 expected | polyarticular juvenile idiopathic arthritis | Duke University | Recruiting | No outcome recorded |
| Phase 3 | NCT05379322 | Mar 2023 | rheumatoid arthritis | Abu Dhabi Stem Cells Center | Withdrawn | No outcome recorded |
| Phase 3 | NCT04870203 | Jul 2021 → Mar 2027 expected | rheumatoid arthritis | University Hospital, Bordeaux | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04610476 | Oct 2020 → Oct 2024 | psoriatic arthritis, substance withdrawal syndrome | University of Erlangen-Nürnberg Medical School | Unknown | No outcome recorded |
| Phase 3 | NCT03728478 | May 2019 → Feb 2025 overdue | oligoarticular juvenile idiopathic arthritis, rheumatoid factor-negative juvenile idiopathic arthritis | Gaslini Institute | Recruiting | No outcome recorded |
| Phase 3 | NCT04079374 | Sep 2018 → Dec 2021 | rheumatoid arthritis | Joint Stock Company "Farmak" | Unknown | No outcome recorded |
| Phase 3 | NCT02840175 | May 2017 → Oct 2019 | juvenile idiopathic arthritis | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 3 | NCT03073200 | Mar 2017 → Feb 2019 | psoriasis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT02986139 | Nov 2016 → Sep 2017 | arthropathy | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT03403140 | Oct 2016 → Sep 2018 | rheumatoid arthritis | Gema Biotech S.A. | Unknown | No outcome recorded |
| Phase 3 | NCT02685904 | Sep 2016 → Jan 2018 | ankylosing spondylitis | Mycenax Biotech Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT03332719 | Feb 2016 → Mar 2017 | rheumatoid arthritis | Gema Biotech S.A. | Completed | No outcome recorded |
| Phase 3 | NCT02378506 | Apr 2015 → May 2016 | rheumatoid arthritis | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT02376790 | Mar 2015 → Jan 2018 | psoriatic arthritis | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT02638259 | Feb 2015 → Dec 2016 | rheumatoid arthritis | Sandoz | Completed | No outcome recorded |
| Phase 3 | NCT02373813 | Feb 2015 → Dec 2019 | rheumatoid arthritis | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT02701205 | Jan 2015 → Jan 2017 | psoriasis | Shanghai Celgen Bio-Pharmaceutical Co.,Ltd | Unknown | No outcome recorded |
| Phase 3 | NCT01900782 | Oct 2013 → Jun 2015 | psoriasis | Novartis Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 3 | NCT01787149 | Sep 2013 → Dec 2017 | — | Mycenax Biotech Inc. | Unknown | No outcome recorded |
| Phase 3 | NCT01394913 | Aug 2013 → Mar 2014 | rheumatoid arthritis | EMS | Withdrawn | No outcome recorded |
| Phase 3 | NCT01709760 | Nov 2012 → Dec 2017 | rheumatoid arthritis | Mycenax Biotech Inc. | Unknown | No outcome recorded |
| Phase 3 | NCT01690299 | Oct 2012 → Jul 2014 | psoriasis, psoriatic arthritis | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT01421069 | Oct 2011 → Feb 2021 | juvenile idiopathic arthritis | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT02164214 | Sep 2011 → Mar 2015 | psoriatic arthritis | Assistance Publique Hopitaux De Marseille | Completed | No outcome recorded |
| Phase 3 | NCT01313221 | Apr 2011 → Dec 2012 | psoriasis | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT01235442 | Sep 2010 → Oct 2011 | psoriasis | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT01001208 | Nov 2009 → Dec 2010 | psoriasis | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT00962741 | Sep 2009 → Jun 2011 | juvenile idiopathic arthritis | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT02779114 | Jan 2009 → Dec 2017 | rheumatoid arthritis | University of Erlangen-Nürnberg Medical School | Unknown | No outcome recorded |
| Phase 3 | NCT00726375 | May 2008 → Jul 2013 | acute graft versus host disease | University of Michigan Rogel Cancer Center | Completed | No outcome recorded |
| Phase 3 | NCT00524381 | Aug 2007 → Jul 2009 | polymyalgia rheumatica | Bispebjerg Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00421174 | Aug 2007 → Jun 2010 | idiopathic interstitial pneumonia | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 3 | NCT00484237 | Apr → Dec 2007 | rheumatoid arthritis | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00434044 | Feb → Jun 2007 | ankylosing spondylitis | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00418717 | Feb → Dec 2007 | rheumatoid arthritis | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00413452 | Dec 2006 → Aug 2007 | rheumatoid arthritis | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT00445770 | Jul 2006 → Jul 2010 | rheumatoid arthritis | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00333034 | Jun 2006 → May 2007 | psoriasis | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00443950 | Jun 2006 → Jul 2007 | rheumatoid arthritis | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00249041 | Oct 2005 → Dec 2006 | rheumatoid arthritis | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT00141921 | Aug 2005 → Dec 2011 | psoriasis | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT00121615 | Oct 2004 → ? | psoriasis | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT00116181 | Oct 2004 → Jan 2007 | psoriasis | Rockefeller University | Completed | No outcome recorded |
| Phase 3 | NCT00078819 | Sep 2004 → Feb 2006 | psoriasis | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT00418548 | Jun 2004 → Feb 2005 | ankylosing spondylitis | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00111449 | Jun 2003 → ? | psoriasis | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT00317538 | Jun 2003 → Nov 2004 | rheumatoid arthritis | Centocor Ortho Biotech Services, L.L.C. | Completed | No outcome recorded |
| Phase 3 | NCT00046904 | May 2003 → Sep 2007 | hypoproteinemia, hypercatabolic | Mayo Clinic | Completed | No outcome recorded |
| Phase 3 | NCT00111436 | Apr 2003 → Jul 2005 | psoriasis | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT00421980 | Jun 2002 → Jul 2004 | ankylosing spondylitis | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00356356 | Apr 2002 → Aug 2006 | ankylosing spondylitis | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT00421915 | Mar → Aug 2002 | ankylosing spondylitis | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00078806 | Jun 2001 → May 2004 | juvenile idiopathic arthritis | Amgen | Terminated | No outcome recorded |
| Phase 3 | NCT00393471 | Oct 2000 → Oct 2001 | rheumatoid arthritis | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT03781375 | Aug 2000 → Jun 2002 | polyarticular juvenile rheumatoid arthritis | Amgen | Terminated | No outcome recorded |
| Phase 3 | NCT00317499 | Apr 2000 → Jun 2002 | psoriasis, psoriatic arthritis | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT00356590 | Dec 1998 → Dec 2008 | rheumatoid arthritis | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT00357903 | Apr 1997 → Dec 2008 | rheumatoid arthritis | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT00110903 | — | rheumatoid arthritis | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT00111111 | — | psoriasis | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT00012506 | — | juvenile idiopathic arthritis, uveitis | National Eye Institute (NEI) | Unknown | No outcome recorded |
| Phase 477 trials | ||||||
| Phase 4 | NCT07352566 | Aug 2026 → Jun 2030 expected | atopic eczema, psoriasis | University of California, San Francisco | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07149792 | Jul 2025 → Dec 2026 expected | psoriasis, psoriatic arthritis | Taichung Veterans General Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT05164198 | Jan 2022 → Oct 2024 | ankylosing spondylitis | Hanyang University Seoul Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT05115903 | Dec 2021 → Jul 2024 | spondyloarthropathy | University Health Network, Toronto | Unknown | No outcome recorded |
| Phase 4 | NCT05080218 | Nov 2021 → Apr 2024 | psoriatic arthritis, spondyloarthropathy | Jeffrey Curtis | Completed | No outcome recorded |
| Phase 4 | NCT05135312 | Aug 2021 → Aug 2022 | psoriasis, psoriatic arthritis | OptiSkin Medical | Unknown | No outcome recorded |
| Phase 4 | NCT03636373 | Oct 2019 → Aug 2021 | gout | Rutgers, The State University of New Jersey | Terminated | No outcome recorded |
| Phase 4 | NCT04077957 | Oct 2019 → Oct 2021 | ankylosing spondylitis | Nanfang Hospital, Southern Medical University | Unknown | No outcome recorded |
| Phase 4 | NCT03813771 | Mar 2019 → Feb 2023 | rheumatoid arthritis | University of Leeds | Unknown | No outcome recorded |
| Phase 4 | NCT03649061 | Jun 2018 → Jul 2022 | rheumatoid arthritis | P. Verschueren | Completed | No outcome recorded |
| Phase 4 | NCT02713997 | Dec 2016 → Jul 2023 | chronic pancreatitis | University of Minnesota | Completed | No outcome recorded |
| Phase 4 | NCT02749370 | May 2016 → Aug 2017 | psoriasis | Amgen | Completed | No outcome recorded |
| Phase 4 | NCT02714634 | Mar 2016 → Mar 2029 expected | rheumatoid arthritis | University Hospital, Strasbourg, France | Recruiting | No outcome recorded |
| Phase 4 | NCT02878161 | Jan 2016 → Dec 2019 | rheumatoid arthritis | Fen Li | Unknown | No outcome recorded |
| Phase 4 | NCT02638896 | Jan 2016 → Feb 2017 | ankylosing spondylitis | Zhixiang Huang | Unknown | No outcome recorded |
| Phase 4 | NCT02509026 | Sep 2015 → May 2019 | ankylosing spondylitis | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT02274792 | Jan → Nov 2015 | psoriasis | Amgen | Completed | No outcome recorded |
| Phase 4 | NCT02960035 | Apr 2014 → Sep 2016 | spondyloarthropathy | Sun Yat-sen University | Completed | No outcome recorded |
| Phase 4 | NCT02109289 | Apr 2014 → Nov 2016 | rheumatoid arthritis, vasculitis | Innovaderm Research Inc. | Terminated | No outcome recorded |
| Phase 4 | NCT01971346 | Mar 2014 → Nov 2017 | psoriasis | University of Michigan | Completed | No outcome recorded |
| Phase 4 | NCT02364479 | Feb 2014 → Jul 2016 | spondyloarthropathy | Sun Yat-sen University | Completed | No outcome recorded |
| Phase 4 | NCT01783015 | Sep 2013 → Aug 2014 | rheumatoid arthritis | Pfizer | Terminated | No outcome recorded |
| Phase 4 | NCT02132234 | Jun 2013 → Jul 2014 | ankylosing spondylitis, hypertensive disorder, psoriatic arthritis | Jagiellonian University | Unknown | No outcome recorded |
| Phase 4 | NCT01927757 | May 2013 → Jun 2015 | rheumatoid arthritis | Amgen | Terminated | No outcome recorded |
| Phase 4 | NCT01578850 | Jul 2012 → Mar 2015 | rheumatoid arthritis | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT01604629 | Jul 2012 → Apr 2015 | spondyloarthropathy | Spanish Clinical Pharmacology Society | Completed | No outcome recorded |
| Phase 4 | NCT01602302 | Jun 2012 → Nov 2020 | rheumatoid arthritis | Medical University of Graz | Terminated | No outcome recorded |
| Phase 4 | NCT01543204 | Feb 2012 → May 2015 | psoriasis | Amgen | Terminated | No outcome recorded |
| Phase 4 | NCT01548768 | Oct 2011 → Sep 2019 | rheumatoid arthritis | Columbia University | Completed | No outcome recorded |
| Phase 4 | NCT01295151 | Aug 2011 → Nov 2015 | rheumatoid arthritis | Julia Brown | Completed | No outcome recorded |
| Phase 4 | NCT01313208 | Mar 2011 → Feb 2013 | rheumatoid arthritis | Amgen | Completed | No outcome recorded |
| Phase 4 | NCT01372930 | Apr 2010 → Jul 2014 | myocardial infarction | Xijing Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01132235 | Apr → Dec 2010 | psoriasis | Florida Academic Dermatology Centers | Unknown | No outcome recorded |
| Phase 4 | NCT00992394 | Jan 2010 → Apr 2013 | psoriasis | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00967538 | Sep 2009 → Jul 2014 | psoriasis | Innovaderm Research Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00913458 | Sep 2009 → Jun 2012 | rheumatoid arthritis | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00910273 | Jul 2009 → Oct 2011 | ankylosing spondylitis | Pfizer | Terminated | No outcome recorded |
| Phase 4 | NCT00848354 | Jun 2009 → Apr 2013 | rheumatoid arthritis | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00837434 | Mar 2009 → Nov 2013 | rheumatoid arthritis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 4 | NCT00833729 | Feb 2009 → Feb 2010 | psoriasis | Dermatrials Research | Completed | No outcome recorded |
| Phase 4 | NCT00796705 | Nov 2008 → Oct 2010 | rheumatoid arthritis | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
| Phase 4 | NCT00783536 | Nov 2008 → Jun 2010 | rheumatoid arthritis | Wyeth is now a wholly owned subsidiary of Pfizer | Withdrawn | No outcome recorded |
| Phase 4 | NCT00768053 | Oct 2008 → Mar 2010 | rheumatoid arthritis | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00791765 | Oct 2008 → Jan 2010 | psoriasis | Amgen | Completed | No outcome recorded |
| Phase 4 | NCT00780793 | Sep 2008 → Sep 2011 | rheumatoid arthritis | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 4 | NCT02489760 | Jul 2008 → Dec 2015 | ankylosing spondylitis | Chung Shan Medical University | Unknown | No outcome recorded |
| Phase 4 | NCT00663052 | Jun 2008 → Jan 2010 | psoriasis | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00654368 | Jun 2008 → Dec 2012 | rheumatoid arthritis | Amgen | Completed | No outcome recorded |
| Phase 4 | NCT00726804 | Mar 2008 → May 2012 | spondyloarthropathy | Glostrup University Hospital, Copenhagen | Terminated | No outcome recorded |
| Phase 4 | NCT01072058 | Feb 2008 → Feb 2011 | ankylosing spondylitis | University of Sao Paulo | Unknown | No outcome recorded |
| Phase 4 | NCT00581555 | Oct 2007 → Nov 2009 | psoriasis | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT01053819 | Sep 2007 → Apr 2012 | melanoma, psoriasis, skin cancer | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 4 | NCT00523692 | Sep 2007 → ? | rheumatoid arthritis | University Hospital Birmingham | Unknown | No outcome recorded |
| Phase 4 | NCT02915354 | Jul 2007 → Sep 2010 | ankylosing spondylitis | Sun Yat-sen University | Completed | No outcome recorded |
| Phase 4 | NCT00420238 | Jan 2007 → Feb 2009 | ankylosing spondylitis | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00420303 | Jan 2007 → Sep 2008 | spondyloarthropathy | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00873730 | Dec 2006 → Jun 2008 | ankylosing spondylitis | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00410046 | Dec 2006 → Oct 2008 | ankylosing spondylitis | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT01303874 | Sep 2006 → Nov 2010 | rheumatoid arthritis | University of Leeds | Completed | No outcome recorded |
| Phase 4 | NCT00458185 | Aug 2006 → Apr 2007 | ankylosing spondylitis | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00332332 | Mar 2006 → Jul 2009 | psoriasis | Amgen | Completed | No outcome recorded |
| Phase 4 | NCT00581165 | Feb 2006 → Aug 2007 | psoriasis | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00247962 | Dec 2005 → Feb 2008 | ankylosing spondylitis | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00127842 | Aug 2005 | psoriatic arthritis | Amgen | Completed | No outcome recorded |
| Phase 4 | NCT00115219 | May 2005 → ? | rheumatoid arthritis | Amgen | Completed | No outcome recorded |
| Phase 4 | NCT00161655 | Apr 2005 → Aug 2006 | psoriasis, psoriatic arthritis | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00110981 | Mar 2005 → Feb 2006 | psoriasis | Amgen | Completed | No outcome recorded |
| Phase 4 | NCT00195507 | Dec 2004 → Feb 2007 | psoriasis | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00094341 | Oct 2004 → ? | rheumatoid arthritis | Amgen | Completed | No outcome recorded |
| Phase 4 | NCT00133315 | Sep 2004 → Apr 2007 | ankylosing spondylitis, psoriatic arthritis | Hvidovre University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00252668 | Jun 2004 → Sep 2005 | rheumatoid arthritis | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00099554 | May 2004 → ? | rheumatoid arthritis | Amgen | Completed | No outcome recorded |
| Phase 4 | NCT00444340 | Apr 2004 → Jul 2007 | ankylosing spondylitis | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00244556 | Mar 2003 → May 2004 | rheumatoid arthritis | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00546533 | Jan 2003 → Feb 2005 | rheumatoid arthritis | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00132418 | Apr 2000 → Feb 2004 | rheumatoid arthritis | Amgen | Completed | No outcome recorded |
| Phase 4 | NCT00111124 | — | psoriasis | Amgen | Completed | No outcome recorded |
| Phase not applicable17 trials | ||||||
| — | NCT07184853 | Sep 2025 → Sep 2027 expected | graft versus host disease | First Affiliated Hospital of Zhejiang University | Recruiting | No outcome recorded |
| — | NCT05305066 | Feb 2023 → Dec 2028 expected | rheumatoid arthritis | Marie Hudson, MD | Recruiting | No outcome recorded |
| — | NCT04378621 | Oct 2020 → Sep 2025 | depressive disorder, rheumatoid arthritis, subjective cognitive decline | Vastra Gotaland Region | Unknown | No outcome recorded |
| — | NCT02722772 | Feb 2016 → Jul 2017 | osteoarthritis, knee | First Affiliated Hospital of Harbin Medical University | Unknown | No outcome recorded |
| — | NCT02722811 | Feb 2016 → Jul 2017 | osteoarthritis, knee | First Affiliated Hospital of Harbin Medical University | Unknown | No outcome recorded |
| — | NCT02031211 | Jun 2014 → Oct 2016 | complex regional pain syndrome | Stanford University | Withdrawn | No outcome recorded |
| — | NCT02258282 | May 2014 → Dec 2022 | psoriasis | Chengdu PLA General Hospital | Unknown | No outcome recorded |
| — | NCT01361542 | Feb → Dec 2011 | ankylosing spondylitis | All India Institute of Medical Sciences | Completed | No outcome recorded |
| — | NCT00931957 | Oct 2010 → Oct 2012 | Behcet disease, uveal disorder | Tehran University of Medical Sciences | Unknown | No outcome recorded |
| — | NCT01170715 | Jul 2010 → Sep 2013 | psoriasis | Rockefeller University | Completed | No outcome recorded |
| — | NCT00825344 | Jan 2009 → Nov 2011 | — | Johns Hopkins University | Completed | No outcome recorded |
| — | NCT01276314 | Jan 2009 → May 2015 | drug allergy | Chang Gung Memorial Hospital | Completed | No outcome recorded |
| — | NCT00800982 | Oct 2008 → Jan 2012 | psoriasis | University of California, San Francisco | Completed | No outcome recorded |
| — | NCT00477191 | May 2007 → Dec 2013 | hyperlipidemia, hypertensive disorder, metabolic syndrome X, obesity disorder +1 | Massachusetts General Hospital | Terminated | No outcome recorded |
| — | NCT00276029 | Dec 2003 → Sep 2004 | asthma | University Hospitals, Leicester | Completed | No outcome recorded |
| — | NCT00205231 | May 2002 → May 2004 | HIV infectious disease | University of Wisconsin, Madison | Completed | No outcome recorded |
| — | NCT00001116 | ? → Jun 2000 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Also used as a comparator or background therapy in 113 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07519005 Background | Jan → Feb 2026 overdue | liver failure | Xijing Hospital | Active not recruiting | No outcome recorded |
| Phase 19 trials | ||||||
| Phase 1 | NCT04254627 Background | Sep 2021 → Sep 2025 | persian gulf syndrome | Nova Southeastern University | Completed | No outcome recorded |
| Phase 1 | NCT03792841 Background | Feb 2019 → Jun 2023 | castration-resistant prostate carcinoma | Amgen | Terminated | No outcome recorded |
| Phase 1 | NCT02481180 Comparator | Jul 2015 → Nov 2017 | rheumatoid arthritis | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Terminated | No outcome recorded |
| Phase 1 | NCT01635686 Comparator | Sep 2012 → Jun 2013 | rheumatoid arthritis | Daewoong Pharmaceutical Co. LTD. | Unknown | No outcome recorded |
| Phase 1 | NCT01431404 Comparator | Aug 2011 → Mar 2012 | — | Hanwha Chemical | Completed | No outcome recorded |
| Phase 1 | NCT01276847 Comparator | Mar → Dec 2011 | psoriasis | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT01716637 Comparator | Feb 2010 → Oct 2015 | Alzheimer disease | Life Extension Foundation Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00112385 Comparator | Mar 2006 → Jun 2010 | dermatomyositis | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 1 | NCT02799498 Comparator | Oct 2003 → Jan 2004 | — | Amgen | Completed | No outcome recorded |
| Phase 1/26 trials | ||||||
| Phase 1/2 | NCT04082910 Background | Sep 2019 → Dec 2022 | cancer, hematopoietic and lymphoid cell neoplasm | Chinese PLA General Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT03160001 Background | Aug 2017 → Aug 2018 | rheumatoid arthritis | Faiq Gorial | Completed | No outcome recorded |
| Phase 1/2 | NCT02821026 Background | May 2016 → Nov 2019 | type 1 diabetes mellitus | University of Alberta | Completed | No outcome recorded |
| Phase 1/2 | NCT00784966 Comparator | Aug 2011 → Sep 2015 | type 1 diabetes mellitus | Virginia Commonwealth University | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT00888628 Background | May 2009 → Aug 2014 | type 1 diabetes mellitus | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT00566813 Comparator | Nov 2004 → Jul 2010 | type 1 diabetes mellitus | University of Illinois at Chicago | Completed | No outcome recorded |
| Phase 212 trials | ||||||
| Phase 2 | NCT06075706 Comparator | Nov 2023 → Feb 2026 overdue | acute graft versus host disease | medac GmbH | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04118556 Comparator | Dec 2021 → Apr 2026 | acute graft versus host disease | Mats Remberger | Terminated | No outcome recorded |
| Phase 2 | NCT02464878 Background | Jan 2017 → Nov 2022 | type 1 diabetes mellitus | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 2 | NCT02862574 Background | Dec 2016 → Jun 2017 | rheumatoid arthritis | Gilead Sciences | Terminated | No outcome recorded |
| Phase 2 | NCT02694770 Comparator | Jul 2016 → Sep 2017 | acute graft versus host disease | AbGenomics B.V Taiwan Branch | Withdrawn | No outcome recorded |
| Phase 2 | NCT00789308 Background | Jul 2008 → Jul 2013 | type 1 diabetes mellitus | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT00713544 Comparator | Jul 2008 → Apr 2009 | rheumatoid arthritis | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00520572 Comparator | Aug 2007 → Mar 2009 | rheumatoid arthritis | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00434850 Background | Oct 2006 → Sep 2011 | type 1 diabetes mellitus | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT00298272 Background | May 2006 → Apr 2009 | rheumatoid arthritis | Biogen | Terminated | No outcome recorded |
| Phase 2 | NCT00134394 Background | Feb 2005 → Dec 2007 | psoriasis | University of Medicine and Dentistry of New Jersey | Completed | No outcome recorded |
| Phase 2 | NCT00293202 Comparator | Jan 2005 → Mar 2008 | end stage renal failure | Kaysen, George A., M.D., Ph.D. | Terminated | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT05871086 Background | May → Dec 2023 | juvenile idiopathic arthritis | Nourhan Elsherif | Unknown | No outcome recorded |
| Phase 2/3 | NCT02809781 Comparator | Jun 2016 → Aug 2018 | ankylosing spondylitis, ankylosis, disease of bone structure | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Unknown | No outcome recorded |
| Phase 2/3 | NCT01030120 Comparator | Dec 2010 → Jul 2012 | chronic idiopathic urticaria | University of Utah | Withdrawn | No outcome recorded |
| Phase 333 trials | ||||||
| Phase 3 | NCT06596772 Comparator | Oct 2024 → Oct 2025 overdue | rheumatoid arthritis | mAbxience Research S.L. | Recruiting | No outcome recorded |
| Phase 3 | NCT02987257 Comparator | Mar 2023 → Oct 2025 | Stevens-Johnson syndrome | Vanderbilt University Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT03451851 Comparator | Jul 2018 → Jul 2023 overdue | psoriasis | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02913261 Comparator | Mar 2017 → Jun 2019 | acute graft versus host disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02471144 Comparator | Sep 2015 → Dec 2018 | psoriasis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02346240 Comparator | Feb 2015 → Mar 2016 | psoriasis | UCB Biopharma S.P.R.L. | Completed | No outcome recorded |
| Phase 3 | NCT02357069 Comparator | Feb 2015 → Dec 2016 | rheumatoid arthritis | LG Life Sciences | Unknown | No outcome recorded |
| Phase 3 | NCT02308163 Comparator | Aug 2014 → Jan 2017 | rheumatoid arthritis | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 3 | NCT02134210 Comparator | Jun 2014 → Jul 2015 | psoriasis | Coherus Oncology, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02115750 Comparator | May 2014 → Oct 2015 | rheumatoid arthritis | Coherus Oncology, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT04345458 Comparator | Mar 2014 → Jul 2015 | ankylosing spondylitis | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT01936688 Comparator | Sep 2013 → Aug 2018 | psoriasis | Sun Pharmaceutical Industries, Inc. | Withdrawn | No outcome recorded |
| Phase 3 | NCT01901185 Background | Jun → Dec 2013 | psoriatic arthritis | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT01895309 Comparator | Jun 2013 → Apr 2014 | rheumatoid arthritis | Samsung Bioepis Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT01891864 Comparator | Jun 2013 → Jun 2014 | psoriasis | Sandoz | Completed | No outcome recorded |
| Phase 3 | NCT01764997 Comparator | Apr 2013 → Jan 2015 | rheumatoid arthritis | Sanofi | Terminated | No outcome recorded |
| Phase 3 | NCT01729754 Comparator | Feb 2013 → Sep 2015 | psoriasis | Sun Pharmaceutical Industries, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01646177 Comparator | Jul 2012 → May 2014 | psoriasis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01597245 Comparator | May 2012 → Mar 2014 | psoriasis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01724268 Comparator | May 2012 → May 2014 | rheumatoid arthritis | Hamad Medical Corporation | Unknown | No outcome recorded |
| Phase 3 | NCT01358578 Comparator | Jun 2011 → Jul 2013 | psoriasis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01258738 Comparator | Feb 2011 → Nov 2012 | ankylosing spondylitis | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT01270997 Comparator | Dec 2010 → May 2012 | rheumatoid arthritis | Hanwha Chemical | Completed | No outcome recorded |
| Phase 3 | NCT01241591 Comparator | Nov 2010 → Jan 2013 | psoriasis | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00710580 Comparator | Jul 2008 → Apr 2009 | psoriasis | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT00691964 Comparator | May 2008 → Mar 2009 | psoriasis | AbbVie | Completed | No outcome recorded |
| Phase 3 | NCT03414502 Comparator | Dec 2007 → Mar 2028 expected | rheumatoid arthritis | University of Nebraska | Recruiting | No outcome recorded |
| Phase 3 | NCT00679042 Background | Sep 2007 → Jul 2017 overdue | type 1 diabetes mellitus | CellTrans Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT00454584 Comparator | Mar 2007 → Jan 2008 | psoriasis | Centocor, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00468117 Background | Jan 2007 → Jul 2015 | type 1 diabetes mellitus | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 3 | NCT00434811 Background | Oct 2006 → Sep 2012 | type 1 diabetes mellitus | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 3 | NCT00353119 Comparator | Apr 2006 → Mar 2007 | palmoplantar pustulosis | Innovaderm Research Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00124982 Background | Apr 2005 → Aug 2009 | rheumatoid arthritis | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 443 trials | ||||||
| Phase 4 | NCT06707194 Background | Jun 2025 → Mar 2027 expected | ankylosing spondylitis | Nanfang Hospital, Southern Medical University | Recruiting | No outcome recorded |
| Phase 4 | NCT04985435 Comparator | May 2021 → Sep 2025 overdue | rheumatoid arthritis | R.Bos | Recruiting | No outcome recorded |
| Phase 4 | NCT03976245 Comparator | Mar 2020 → Mar 2025 overdue | rheumatoid arthritis | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Recruiting | No outcome recorded |
| Phase 4 | NCT04086745 Comparator | Feb 2020 → May 2025 | rheumatoid arthritis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT04485325 Comparator | Nov 2019 → Mar 2024 | rheumatoid arthritis | Dr. Frank Behrens | Completed | No outcome recorded |
| Phase 4 | NCT03915964 Comparator | Apr 2019 → May 2025 | rheumatoid arthritis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT03445845 Comparator | Dec 2018 → Sep 2024 | spondyloarthropathy | University Hospital of Saint-Etienne | Completed | No outcome recorded |
| Phase 4 | NCT03100253 Comparator | Mar 2018 → Dec 2021 | rheumatoid arthritis | Mario Negri Institute for Pharmacological Research | Terminated | No outcome recorded |
| Phase 4 | NCT03504072 Comparator | Jan 2018 → Jun 2019 | spondyloarthropathy | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Unknown | No outcome recorded |
| Phase 4 | NCT02374021 Comparator | Jul 2016 → May 2021 | rheumatoid arthritis | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02242474 Comparator | Jul 2015 → Oct 2019 | rheumatoid arthritis | CHU de Quebec-Universite Laval | Unknown | No outcome recorded |
| Phase 4 | NCT02353780 Comparator | Mar 2015 → Dec 2017 | rheumatoid arthritis | Dr. Larry W. Moreland | Terminated | No outcome recorded |
| Phase 4 | NCT02313922 Background | Nov 2014 → Aug 2018 | psoriasis | Zhejiang University | Completed | No outcome recorded |
| Phase 4 | NCT01934933 Comparator | Sep 2014 → Sep 2015 | ankylosing spondylitis | Sun Yat-sen University | Completed | No outcome recorded |
| Phase 4 | NCT02144857 Comparator | May 2014 → Sep 2023 | psoriasis | University of Athens | Unknown | No outcome recorded |
| Phase 4 | NCT02092467 Comparator | Mar 2014 → Jul 2020 | rheumatoid arthritis | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT02236481 Comparator | Jul 2013 → Dec 2017 | rheumatoid arthritis, type 2 diabetes mellitus | Prof. Roberto Giacomelli | Terminated | No outcome recorded |
| Phase 4 | NCT01875991 Background | Jun 2013 → Mar 2014 | psoriasis, rheumatoid arthritis | Amgen | Completed | No outcome recorded |
| Phase 4 | NCT01793519 Comparator | Jan 2013 → Jun 2024 | rheumatoid arthritis | Georgetown University | Unknown | No outcome recorded |
| Phase 4 | NCT01331837 Comparator | Aug 2011 → Mar 2016 | rheumatoid arthritis | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 4 | NCT01400516 Background | Aug 2011 → Jul 2015 | rheumatoid arthritis | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02433184 Comparator | Jul 2011 → Aug 2017 | rheumatoid arthritis | University of Leeds | Completed | No outcome recorded |
| Phase 4 | NCT01298531 Comparator | May 2011 → Jan 2013 | spondyloarthropathy | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT01287715 Comparator | Jan 2011 → Sep 2012 | juvenile idiopathic arthritis | Erasmus Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT01237262 Comparator | Nov 2010 | psoriasis | University of Padova | Unknown | No outcome recorded |
| Phase 4 | NCT01021735 Comparator | Apr 2010 → Dec 2014 | rheumatoid arthritis | University of Glasgow | Completed | No outcome recorded |
| Phase 4 | NCT01000441 Comparator | Dec 2009 → Aug 2013 | rheumatoid arthritis | University Hospital, Strasbourg, France | Completed | No outcome recorded |
| Phase 4 | NCT01009879 Background | Nov 2009 → Feb 2012 | rheumatoid arthritis | University of Pittsburgh | Withdrawn | No outcome recorded |
| Phase 4 | NCT00832364 Background | Oct 2009 → Mar 2010 | psoriasis | Stiefel, a GSK Company | Withdrawn | No outcome recorded |
| Phase 4 | NCT00936065 Comparator | Jul 2009 → Apr 2011 | psoriasis | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00858780 Comparator | Jan 2009 → Jun 2012 | rheumatoid arthritis | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00706797 Comparator | Sep 2008 → Dec 2009 | rheumatoid arthritis | Wyeth is now a wholly owned subsidiary of Pfizer | Terminated | No outcome recorded |
| Phase 4 | NCT00640393 Comparator | Apr 2008 → Feb 2010 | psoriasis | Innovaderm Research Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00565409 Comparator | Mar 2008 → May 2011 | rheumatoid arthritis | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00581100 Comparator | Sep 2007 → Aug 2009 | psoriasis | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00422227 Comparator | Jun 2007 → Mar 2009 | rheumatoid arthritis | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00443430 Comparator | May 2007 → Oct 2010 | juvenile chronic polyarthritis, juvenile idiopathic arthritis, polyarticular juvenile rheumatoid arthritis | Seattle Children's Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00432406 Comparator | May 2006 → Mar 2009 | psoriatic arthritis | Chinese University of Hong Kong | Completed | No outcome recorded |
| Phase 4 | NCT00346294 Background | Jan → Mar 2006 | rheumatoid arthritis | Amgen | Completed | No outcome recorded |
| Phase 4 | NCT00245960 Comparator | Dec 2005 → Mar 2008 | psoriatic arthritis | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00688103 Comparator | Jun 2005 → Oct 2008 | rheumatoid arthritis | Japan Biological Agent Study Integrated Consortium | Completed | No outcome recorded |
| Phase 4 | NCT00195494 Comparator | Nov 2004 → Mar 2008 | rheumatoid arthritis | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00259610 Comparator | May 2004 → Jun 2009 | rheumatoid arthritis | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase not applicable6 trials | ||||||
| — | NCT03033095 Background | Jul 2016 → Jul 2017 | ankylosing spondylitis | University Hospital, Grenoble | Completed | No outcome recorded |
| — | NCT01657513 Background | Jun 2012 → Jul 2013 | psoriasis | University Hospital, Gentofte, Copenhagen | Unknown | No outcome recorded |
| — | NCT01610947 Comparator | May 2012 → Oct 2018 | spondyloarthropathy | University Hospital, Montpellier | Completed | No outcome recorded |
| — | NCT00405275 Comparator | Jul 2007 → Dec 2011 | rheumatoid arthritis | US Department of Veterans Affairs | Completed | No outcome recorded |
| — | NCT00413400 Comparator | Dec 2006 → Sep 2009 | metabolic syndrome X | Massachusetts General Hospital | Completed | No outcome recorded |
| — | NCT00409318 Comparator | Apr 2004 → May 2005 | metabolic syndrome X | Massachusetts General Hospital | Completed | No outcome recorded |
Press releases naming this drug 21 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-05-17 | Novartis Pharmaceuticals | US Supreme Court denies Sandoz petition to review biosimilar Erelzi® (etanercept-szzs) case novartis.com ↗ |
| 2020-07-01 | Amgen | Appeals Court Affirms Validity Of Enbrel® (etanercept) Patents Injunction Against Sandoz's Infringement Stands amgen.com ↗ |
| 2019-11-12 | Novartis Pharmaceuticals | Sandoz presents real-world data showing effectiveness of Erelzi® (etanercept-szzs) in rheumatic disease treatment novartis.com ↗ |
| 2019-08-09 | Novartis Pharmaceuticals | Sandoz will appeal District Court of New Jersey ruling in biosimilar Erelzi® (etanercept-szzs) US patent case novartis.com ↗ |
| 2019-08-09 | Amgen | Amgen Wins Patent Case On Enbrel® (etanercept) amgen.com ↗ |
| 2019-07-26 | Takeda | Termination of Co-promotion in Japan of Rheumatoid Arthritis Drug Enbrel ® takeda.com ↗ |
| 2018-10-24 | Amgen | First Head-to-Head Trial of a TNF Inhibitor Versus Methotrexate Monotherapy in Psoriatic Arthritis Shows ENBREL® (Etanercept) Monotherapy and Combination Therapy Both Superior to Methotrexate amgen.com ↗ |
| 2018-06-15 | Novartis Pharmaceuticals | Sandoz presents new long-term and switching data for biosimilars Zessly® (infliximab) and Erelzi® (etanercept) in rheumatoid arthritis novartis.com ↗ |
| 2017-11-17 | Amgen | Amgen Launches The ENBREL Mini™ Single-Dose Prefilled Cartridge With AutoTouch™ Reusable Autoinjector That Is Ergonomically Designed For Patients amgen.com ↗ |
| 2017-06-27 | Novartis Pharmaceuticals | Sandoz receives approval in Europe for Erelzi® (biosimilar etanercept) to treat multiple inflammatory diseases novartis.com ↗ |
| 2017-04-21 | Novartis Pharmaceuticals | Sandoz proposed biosimilars rituximab and etanercept recommended for approval in Europe* novartis.com ↗ |
| 2016-11-18 | Novartis Pharmaceuticals | Innovative study with three treatment switches confirms Sandoz biosimilar etanercept has equivalent efficacy to originator novartis.com ↗ |
| 2016-11-04 | Amgen | FDA Approves Expanded Use Of ENBREL® (etanercept) To Treat Children With Chronic Moderate-To-Severe Plaque Psoriasis amgen.com ↗ |
| 2016-07-13 | Novartis Pharmaceuticals | Sandoz biosimilar etanercept recommended by FDA advisory committee for approval to treat multiple inflammatory diseases novartis.com ↗ |
| 2016-07-07 | Novartis Pharmaceuticals | New data shows Sandoz biosimilar etanercept candidate has equivalent efficacy to originator product novartis.com ↗ |
| 2016-06-09 | Novartis Pharmaceuticals | New data demonstrates Sandoz' etanercept and rituximab biosimilar candidates bioequivalent to originator products novartis.com ↗ |
| 2016-03-10 | Amgen | FDA Accepts Amgen's Supplemental Biologics License Application For The Expanded Use Of Enbrel® (Etanercept) To Treat Pediatric Patients With Chronic Severe Plaque Psoriasis amgen.com ↗ |
| 2016-01-12 | Daiichi Sankyo | Daiichi Sankyo Announces Results of Phase 3 International Joint Trial (RApsody) of Investigational Etanercept Biosimilar daiichisankyo.com ↗ |
| 2015-12-08 | Novartis Pharmaceuticals | Sandoz advances its biosimilars program with European Medicines Agency (EMA) acceptance of regulatory submission for biosimilar etanercept novartis.com ↗ |
| 2015-10-02 | Novartis Pharmaceuticals | FDA accepts Sandoz regulatory submission for a proposed biosimilar etanercept novartis.com ↗ |
| 2014-08-18 | Daiichi Sankyo | Initiation of Phase 3 Trial of CHS-0214 (Investigational Etanercept Biosimilar) in Japan (RApsody) daiichisankyo.com ↗ |
Evidence & citations 25 cited values
Every value below carries the sentence it was read from. 377 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | etanercept | “The BAT in this study was identified by the investigator prior to patient randomization among the following treatments currently used in this setting: anti-thymocyte globulin...” NCT02913261 ↗338“The BAT in this study will freely be identified by the Investigator prior to patient randomization and may include treatments such as: anti-thymocyte globulin (ATG),...” NCT04118556 ↗ “The investigator proposes to perform a Phase I study assessing safety, efficacy, and biomarker response to the therapeutic interventions of Etanercept followed by mifepristone...” NCT04255498 ↗ “To be given subcutaneously via a prefilled syringe/autoinjector (etanercept, adalimumab, certolizumab pegol, golimumab) or intravenously via infusion (infliximab) at increasing...” NCT05115903 ↗ “This withdrawn study was to assess the safety and efficacy of secukinumab compared to etanercept and placebo in patients who have moderate to severe, chronic, plaque-type psoriasis.” NCT01900782 ↗ “RA treated with subcutaneous TNF-blockers (etanercept or adalimumab) at stable and standard dosage for 1 year or more, as monotherapy or associated with stable conventional DMARD;” NCT00780793 ↗ “TNF-a inhibitors: Etanercept (Enbrel, Benapali), Infliximab (Remicade, Inflectra, Flixabi), Adalimumab (Humira, Imraldi, AMGEVITA), Certolizumabpegol (Cimzia), Golimumab (Simponi)” NCT04378621 ↗ “Sandoz etanercept (SDZ ETN; GP2015) is an etanercept biosimilar with equivalent efficacy and comparable safety and immunogenicity to reference etanercept (ETN)” PMID 31138316 ↗ May 2019 “An approved stable subcutaneous formulation of one of the following TNF inhibitors may include adalimumab, certolizumab, etanercept, or golimumab.” NCT02862574 ↗ “Enbrel®, also known as etanercept, has already been approved by the Federal Food Drug Administration for the treatment of psoriatic arthritis.” NCT00111124 ↗ “Study Comparing Enbrel (Etanercept) Plus Methotrexate Versus Enbrel Alone in Active Rheumatoid Arthritis Despite Current Methotrexate Therapy” NCT00244556 ↗ “We also found that a medicine called ETANercept can slow down neuroblastoma growth, which might enhance the effects of the modified cells.” NCT03294954 ↗ “Any of the anti-TNF therapies (Infliximab, Adalimumab, Etanercept, etc.)administered at the approved label dose for at least 3 months” NCT00124982 ↗ “Participants were randomised to anakinra or to a TNFi (i.e., adalimumab, certolizumab pegol, etanercept, infliximab, or golimumab)” PMID 31513665 ↗ Sep 2019 “OBJECTIVE: To evaluate the safety of etanercept in patients with rheumatoid arthritis (RA) and concomitant comorbidities.” PMID 17470434 ↗ Apr 2007 “The drug, called Enbrel (or etanercept), is a protein that is given twice weekly by injection underneath the skin.” NCT00000433 ↗ “Participants received a TNF inhibitor (adalimumab or etanercept) administered according to approved local labeling” NCT03915964 ↗ “such as Etanercept and infliximab, pentostatin, sirolimus, mycophenolate mofetil and extracorporeal photopheresis” NCT02694770 ↗ “extracorporeal photopheresis (ECP), anti-thymocyte globulin (ATG), etanercept, infliximab or ruxolitinib (RUX)” NCT06075706 ↗ “We evaluated the safety and efficacy of etanercept, a TNF antagonist, for the treatment of plaque psoriasis.” PMID 14627786 ↗ Nov 2003 “Etanercept 50 mg iv 1 hour before transplant and 25 mg s.c. on days 3, 7,and 10 post-transplant” NCT00679042 ↗ “etanercept 50 mg IV before islet transplant, 25 mg subcutaneously post-transplant days 3, 7, 10” NCT00566813 ↗ “adalimumab at 40 mg every 2 weeks or etanercept 50 mg per week according to treatments history” NCT04870203 ↗ “TNF antagonist as prescribed in clinical practice (such as etanercept or adalimumab)” NCT01400516 ↗ “a TNF inhibitor (adalimumab, certolizumab, etanercept, golimumab or infliximab)” NCT01724268 ↗ “Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in” PMID 20574649 ↗ Jun 2010 “Etanercept improved clinical outcomes in patients with SJS-TEN.” PMID 29400697 ↗ Feb 2018 “namely etanercept (receptor fusion protein) 50 mg sc per week” NCT05305066 ↗ “Etanercept at 50mg weekly for the duration of the study” NCT01361542 ↗ “etanercept: 50mg per week in subcutaneous injection” NCT03445845 ↗ “Adalimumab, etanercept, certolizumab, or golimumab” NCT05379322 ↗ “Etanercept subcutaneous injections 50 mg weekly” NCT04985435 ↗ “Methotrexate or leflunomide + etanercept or” NCT02714634 ↗ “Etanercept (anti-TNF-α, 25 mg twice weekly)” NCT07519005 ↗ “Etanercept (Enbrel) or Golimumab (Simponi)” NCT02456363 ↗ “* Etanercept - 0.8 mg/kg/dose once weekly” NCT05871086 ↗ “Etanercept ≥63 kg (138 lb) 50 mg weekly” NCT06654882 ↗ “Etanercept 25mg, single dose” NCT01145950 ↗ “Etanercept: 50 mg / 10 days” NCT01604629 ↗ “Enbrel (Etanercept 25mg)” NCT01725620 ↗ “Etanercept (Enbrel®)” NCT02779114 ↗ “Enbrel (etanercept)” NCT00421915 ↗ “Enbrel (etanercept)” NCT01895309 ↗ “Enbrel (etanercept)” NCT06596772 ↗ “Enbrel (etanercept)” NCT00410046 ↗ “Etanercept (Enbrel)” NCT07149792 ↗ “25mg etanercept” NCT02364479 ↗ “Etanercept” NCT02242474 ↗ “Etanercept” NCT05080218 ↗ |
| Known as | 50mg entanercept(Yisaipu) | “50mg entanercept(Yisaipu)” NCT02364479 ↗ |
| Known as | Benepali | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03813771 ↗ |
| Known as | Drug: Etanercept (Enbrel) | “Drug: Etanercept (Enbrel)” NCT02456363 ↗ |
| Known as | Enbrel | “The purpose of this pilot study is to investigate the safety and efficacy of etanercept (Enbrel™; Amgen) for the treatment of an acute gout attack will be non-inferior to...” NCT03636373 ↗71“This trial is a phase III study to help understand the action of the drug etanercept, trade name Enbrel, for the adult patient with moderate to severe plaque psoriasis and who...” NCT00116181 ↗ “The purpose of this research study is to see how well (compared to placebo) Enbrel® (etanercept) 50 mg twice a week for 12 weeks affects plaque psoriasis of the hands and/or...” NCT00585650 ↗ “This study will investigate the safety and effectiveness of the drug Enbrel (TNFR:Fc) to treat uveitis (eye inflammation) in patients with juvenile rheumatoid arthritis.” NCT00012506 ↗ “Discontinuation of infusion infliximab (Remicade) 3-5mg/kg every 6-8 week, injection of etanercept (Enbrel) 25 mg x 2/week or injection of adalimumab (Humira) 40 mg eow.” NCT00726804 ↗ “OptiSkin is now enrolling a new study to monitor nail changes in patients with nail psoriasis treated with Enbrel® (etanercept) with optical coherence tomography (OCT).” NCT05135312 ↗ “The purpose of this study is to determine the preference of RA patients for the new Enbrel® (etanercept) pre-filled syringe in patients who are already taking Enbrel®.” NCT00094341 ↗ “Single dose of etanercept (ENBREL®) in a pre-filled syringe administered with an auto-injector device manufactured by Scandinavian Health Limited (SHL)” NCT02799498 ↗ “This study will test the effectiveness of etanercept (Enbrel) for treating Sjogren's syndrome-an autoimmune disease that affects the secreting glands.” NCT00001954 ↗ “Double-blind, Randomized, Placebo-controlled Study of Enbrel (Etanercept) in the Treatment of Rheumatoid Arthritis Subjects With Comorbid Disorders” NCT00132418 ↗ “A Study to Assess the Effect of Ustekinumab (Stelara®) and Etanercept (Enbrel®) in Participants With Moderate to Severe Psoriasis (MK-0000-206)” NCT01276847 ↗ “* group 1) - 50 kidneys - examined group - "cured" with etanercept (ENBREL) in the first hour of perfusion by adding drug to perfusion fluid,” NCT01731457 ↗ “An Open-Label Study to Assess the Rate of Failure of an Enbrel® (Etanercept) SureClick™ Auto-injector in Subjects With Rheumatoid Arthritis” NCT00346294 ↗ “Evaluation of the efficacy and safety of etanercept (Enbrel) in patients with active, severe and advanced ankylosing spondylitis.” NCT00420238 ↗ “Etanercept (Enbrel) will be added to help improve the response to standard treatment for graft-versus-host disease (GVHD).” NCT00141713 ↗ “This study will determine if the drug etanercept, also called Enbrel, is effective in producing and maintaining remission” NCT00005007 ↗ “This study will examine the use of etanercept (also called Enbrel or TNFR:Fc) in patients with Wegener's granulomatosis” NCT00001901 ↗ “Two anti-TNFa agents are currently marketed for the treatment of RA; etanercept (Enbrel®) and infliximab (REMICADE®).” NCT00317538 ↗ “The purpose of this study is to assess the antibody formation to Enbrel liquid in subjects with Rheumatoid Arthritis” NCT00249041 ↗ “The drug, called Enbrel (or etanercept), is a protein that is given twice weekly by injection underneath the skin.” NCT00000433 ↗ “Enbrel® 50 mg injectable solution in autoinjector SureClick® contains: 50 mg etanercept and excipients” NCT03332719 ↗ “Patients receive Etanercept or Enbrel (depending on the group) in the form of subcutaneous injections” NCT04079374 ↗ “Treatment of Resistant Langerhans Cell Histiocytosis With Etanercept (ENBREL, IMMUNEX, SEATTLE)” NCT00048373 ↗ “Safety and Efficacy Study of Etanercept (Enbrel) on the Response Rate of HIV-infected Subjects” NCT00091741 ↗ “etanercept (Enbrel) injected subcutaneously 0.8 mg/kg body weight (max 50 mg) once a week” NCT02464033 ↗ “Randomized Controlled 12 Months Trial With Etanercept (Enbrel ®) vs. Sulfasalazine” NCT00844142 ↗ “etanercept(Enbrel®) 50mgs subcutaneous (SC) injections twice weekly for 20 weeks” NCT00797784 ↗ “Study of the Efficacy and Safety of Etanercept (Enbrel) in Adults With Vitiligo” NCT00134368 ↗ “The possible TNF inhibitors are: Remicade, Humira, Enbrel, Cimzia, Simponi.” NCT01548768 ↗ “a tumour necrosis factor alpha (TNFalpha) inhibitor (etanercept, Enbrel)” PMID 15115710 ↗ Apr 2004 “recommended dose of enbrel is 25mg administered twice weekly.” NCT00581165 ↗ “Etanercept (Enbrel) in Undifferentiated Spondyloarthritis” NCT01289730 ↗ “Etanercept (Enbrel) for Juvenile Myelomonocytic Leukemia” NCT00509600 ↗ “Study of TNFR:Fc (Enbrel) in the Treatment of Asthma” NCT00001893 ↗ “Etanercept (Enbrel®; 50 mg once per week, s.c.)” NCT04485325 ↗ “Part 2 will evaluate etanercept (Enbrel).” NCT00001955 ↗ “Adalimumab (Humira) Etanercept (Enbrel)” NCT04985435 ↗ “Drug: Etanercept Injection [Enbrel]” NCT05950724 ↗ “Drug: Etanercept (Enbrel)” NCT07184853 ↗ “Etanercept (Enbrel®)” NCT02779114 ↗ “Enbrel® (Etanercept)” NCT00789308 ↗ “Etanercept (Enbrel)” NCT00965666 ↗ “Enbrel (etanercept)” NCT00434044 ↗ “Enbrel (Etanercept)” NCT00135720 ↗ “Etanercept (Enbrel)” NCT01894412 ↗ “Enbrel (etanercept)” NCT01394913 ↗ “Etanercept (Enbrel)” NCT07149792 ↗ “Enbrel (Etanercept)” NCT00444340 ↗ “Etanercept (Enbrel)” NCT01431404 ↗ “etanercept (Enbrel)” NCT00006070 ↗ “Enbrel (etanercept)” NCT00502879 ↗ “Etanercept (Enbrel)” NCT00524381 ↗ “Enbrel” NCT00410046 ↗ |
| Known as | Enbrel (etanercept) | “Enbrel (etanercept)” NCT02112097 ↗ |
| Known as | EnbrelTM | “etanercept (EnbrelTM)” NCT00706797 ↗ |
| Known as | ENIA11 | “A Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of ENIA11 in Combination With...” NCT01787149 ↗ |
| Known as | Etanercept(Enbrel) | “Etanercept(Enbrel®)” NCT00679042 ↗ |
| Known as | Etanercept- ENBREL as brand name | “Etanercept- ENBREL as brand name” NCT01361542 ↗ |
| Known as | ETN | “The main aim of the VEDERA study (Very Early versus Delayed Etanercept in Rheumatoid Arthritis) is to assess the depth of remission, sustainability of remission and...” PMID 26847108 ↗ Feb 201617“The aim of the Dose Reduction or Discontinuation of Etanercept in Methotrexate-Treated Rheumatoid Arthritis Patients Who Have Achieved a Stable Low Disease Activity-State study...” PMID 25873634 ↗ Apr 2015 “A Multicenter, Open-label, Randomized, Pilot-study to Evaluate the Efficacy and Safety of the Combination of Etanercept (ETN) and Methotrexate and of Etanercept (ETN) Alone in...” NCT00161655 ↗ “BACKGROUND: To describe the 6-year safety and efficacy of etanercept (ETN) in children with extended oligoarticular juvenile idiopathic arthritis (eoJIA), enthesitis-related...” PMID 31122296 ↗ May 2019 “The present paper aims to investigate the effect of psoriatic arthritis (PsA) disease duration on the outcome of treatment with etanercept (ETN) in patients with PsA who also...” PMID 25535650 ↗ Dec 2014 “OBJECTIVE: To evaluate the immunogenicity, safety, and efficacy of etanercept (ETN) manufactured using the serum-free, high-capacity manufacturing (SFHCM) process in patients...” PMID 30451655 ↗ Jan 2019 “To evaluate the efficacy and safety of etanercept (ETN) after 48 weeks in patients with early active non-radiographic axial spondyloarthritis (nr-axSpA).” PMID 26269397 ↗ Aug 2015 “The tumor necrosis factor inhibitors(TNFi) like etanercept(ETN) has been always recommended as the primary treatment option for active AS.” NCT04077957 ↗ “RCT patients were treated with IXE or etanercept (ETN; UNCOVER-2/3), guselkumab (GUS; IXORA-R), or ustekinumab (UST; IXORA-S).” PMID 38521874 ↗ Mar 2024 “Etanercept (ETN) is a dimeric fusion protein consisting of the p75 TNFR linked to the Fc portion of human IgG1” NCT01303874 ↗ “Data from a multicenter, open-label study investigating the immunogenicity of etanercept (ETN) were analyzed.” PMID 20156946 ↗ Feb 2010 “We investigated etanercept (ETN) as a therapeutic option for treating moderate-to-severe persistent asthma.” PMID 21109557 ↗ Nov 2010 “Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in” PMID 20574649 ↗ Jun 2010 “etanercept (ETN) + MTX vs conventional synthetic DMARDs” PMID 24907147 ↗ Jun 2014 “treatment with etanercept (ETN) plus methotrexate (MTX)” PMID 34496979 ↗ Sep 2021 “intermittent etanercept (ETN) therapy” PMID 25087839 ↗ Aug 2014 “two previous etanercept (ETN) trials” PMID 27175292 ↗ Apr 2016 “etanercept (ETN) therapy” PMID 18278836 ↗ Feb 2008 |
| Known as | ETN50 | “we compared efficacy maintenance with etanercept 50 mg once weekly (ETN50) versus placebo (PBO), on a background of methotrexate (MTX) ± other non-biologic, disease-modifying...” PMID 30200078 ↗ Sep 2018 |
| Known as | EU Source Enbrel | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06392074 ↗ |
| Known as | GP2015 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02638259 ↗ |
| Known as | MB04 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06392074 ↗ |
| Known as | Reumatocept | “Reumatocept (etanercept)” NCT01394913 ↗ |
| Known as | SB4 | “SB4 (etanercept) 50 mg/mL PFS and AI” NCT03193203 ↗ |
| Known as | SDZ ETN | “Sandoz etanercept (SDZ ETN; GP2015) is an etanercept biosimilar with equivalent efficacy and comparable safety and immunogenicity to reference etanercept (ETN)” PMID 31138316 ↗ May 2019 |
| Known as | TNFR:Fc | “Adult Rheumatoid Arthritis (RA) patients on etanercept (TNFR:Fc) with well controlled arthritic symptoms will continue on the etanercept (TNFR:Fc) dose administered in their...” NCT00357903 ↗5“In this Phase II clinical trial we will use tumor necrosis factor receptor p75 fusion protein (TNFR:Fc, or etanercept) to treat patients with ankylosing spondylitis (AS).” NCT00000433 ↗ “The purpose of this study is to determine if TNFR:Fc (a molecule that attaches to TNF) can lower the amount of IL-6 in HIV-positive patients.” NCT00001116 ↗ “This study will examine the use of etanercept (also called Enbrel or TNFR:Fc) in patients with Wegener's granulomatosis” NCT00001901 ↗ |
| Known as | US License Enbrel | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06392074 ↗ |
| Known as | Yisaipu | “prefilled liquid etanercept(Yisaipu)” NCT04345458 ↗ |
| Action | Inhibit | “It blocks the action of tumor necrosis factor-alpha (TNF-alpha)” NCT00000433 ↗ |
| Modality | Protein / enzyme biologic | “The drug, called Enbrel (or etanercept), is a protein that is given twice weekly by injection underneath the skin.” NCT00000433 ↗ |
| Route | Subcutaneous | “subcutaneous injection” NCT00001893 ↗ |
| Target | TNF | “TNFR:Fc is a modification of a natural substance that binds to TNF-alpha and neutralizes its activity.” NCT00001116 ↗ |